Endurx Pharmaceuticals
Endurx Pharmaceuticals is a privately held, preclinical-stage biotech founded in 2013 in Tucson, Arizona, developing peptide-directed nanoparticle therapeutics for hard-to-treat cancers. The 1–10 person team is focused on oncology platform R&D with no commercial products currently disclosed.
- Company typePrivate
- Founded2013
- HeadquartersTucson, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Endurx Pharmaceuticals does
Endurx Pharmaceuticals is a privately held, early-stage biotechnology company developing peptide-directed nanoparticle therapeutics aimed at hard-to-treat cancers. Founded in 2013 and headquartered in Tucson, Arizona, the company operates with a team of 1–10 employees, a footprint consistent with a preclinical or early research-stage posture focused on platform R&D rather than commercialized products. The therapeutic approach combines targeting peptides with nanoparticle-based drug delivery to create oncology candidates intended to direct treatment selectively to cancer cells, addressing indications where conventional therapies have limited efficacy.
The underlying platform architecture is described in functional terms as a peptide-directed nanoparticle system, where tumor-homing or receptor-targeting peptides are conjugated to or co-formulated with nanoparticle carriers to improve selectivity and reduce off-target toxicity. Specific payload chemistries, linker technologies, nanoparticle compositions (e.g., polymeric, lipid, or inorganic cores), and the active indication pipeline are not disclosed in the available data, and no patents, trade secrets, or peer-reviewed publications are surfaced in the input.
No business-model details — pricing, GTM motion, revenue mechanics, or customer segments — are observable. The company has no disclosed commercial products, no named customers, no disclosed funding rounds, no partnerships, and no management-team bios in the input data, so the revenue model cannot be characterized beyond R&D-stage research operations that are typical of pre-IND nanomedicine startups funded by grants, angel capital, or early-stage venture investment.
Endurx Pharmaceuticals firmographics
Firmographics- Name
- Endurx Pharmaceuticals
- Website
- https://endurxpharm.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Endurx Pharmaceuticals is a privately held, preclinical-stage biotech founded in 2013 in Tucson, Arizona, developing peptide-directed nanoparticle therapeutics for hard-to-treat cancers. The 1–10 person team is focused on oncology platform R&D with no commercial products currently disclosed.
- Ownership category
- akta.pro rank
Endurx Pharmaceuticals industry classification
Industry- Product category
- Oncology Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in Nanotechnology (541713)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)
- akta.pro secondary industry
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where Endurx Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Tucson
- HQ country
- United States
- HQ region
- North America
Markets served
Endurx Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Endurx Pharmaceuticals product offering
Product offeringCore offering
Endurx Pharmaceuticals develops peptide-directed nanoparticle therapeutics aimed at treating hard-to-treat cancers. The company is engaged in the research and development of targeted drug delivery systems using peptides to direct nanoparticles to cancer cells, positioning itself in the oncology therapeutics space.
Differentiator
Problem solved
Functional benefit
Products and services
- Peptide-directed nanoparticle therapeutics
Companies that use Endurx Pharmaceuticals
Customer profileIdeal customer profiles1 record
Endurx Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Endurx Pharmaceuticals competitors and assessment
Company assessmentEmerging players
- Aprea Therapeutics: Small oncology company leveraging targeted mechanisms (e.g., reactivation of p53) against hard-to-treat cancers, comparable as a small private/public peer in underserved oncology indications.
- Bolt Biotherapeutics: Combines targeted antibodies with immune-stimulating payloads, addressing the same hard-to-treat solid tumor problem with a different but adjacent delivery-driven oncology approach.
- ProfoundBio: Focused on next-generation ADCs and targeted payloads for solid tumors, overlapping with Endurx's targeted-delivery oncology thesis.
Direct peers
- Arrowhead Pharmaceuticals: Uses peptide-targeted ligands (TRiM platform) to deliver nucleic-acid and other payloads to specific cells, sharing the targeted-delivery modality used in oncology therapies.
- Nektar Therapeutics: Operates a polymer–conjugate/peptide-based drug-delivery platform in oncology with clinical-stage programs, directly comparable to a peptide-directed nanoparticle delivery approach.
- CytImmune Sciences: Developer of tumor-targeted gold nanoparticle therapeutics using peptide-based targeting—essentially the same peptide-directed nanoparticle oncology modality as Endurx.
- Mersana Therapeutics: Pursues novel conjugation and payload-platform approaches (e.g., Dolasynthen) to deliver oncology agents with improved tolerability, an adjacent targeted-delivery strategy in oncology.
Broad incumbents
- Genentech (Roche): Broad oncology incumbent with multiple targeted-delivery franchises and large-scale clinical infrastructure; sets the partnership benchmark for any small targeted-oncology platform.
- AbbVie: Established oncology player with deep clinical and commercial reach; a likely acquirer or partner for early targeted-oncology platforms with promising early data.
- Pfizer: Has acquired multiple nanoparticle-based oncology platforms historically and is a frequent partner/acquirer for targeted-delivery oncology assets.
Market position
Strengths3 records
Weaknesses4 records
Competitive moat1 record
Key risks5 records
Key highlights4 records
Customer concentration
Endurx Pharmaceuticals social profiles
Digital presenceEndurx Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Endurx Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles1 record
Endurx Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Endurx Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Endurx Pharmaceuticals
What does Endurx Pharmaceuticals do?
Endurx Pharmaceuticals develops peptide-directed nanoparticle therapeutics aimed at treating hard-to-treat cancers. The company is engaged in the research and development of targeted drug delivery systems using peptides to direct nanoparticles to cancer cells, positioning itself in the oncology therapeutics space.
When was Endurx Pharmaceuticals founded?
Endurx Pharmaceuticals was founded in 2013. It employs 1 to 10 people.
Where is Endurx Pharmaceuticals based?
Endurx Pharmaceuticals is headquartered in Tucson, United States, in the North America region.
Who are Endurx Pharmaceuticals's main competitors?
Emerging players on record are Aprea Therapeutics, Bolt Biotherapeutics and ProfoundBio. Direct peers are Arrowhead Pharmaceuticals, Nektar Therapeutics, CytImmune Sciences and Mersana Therapeutics. Broad incumbents are Genentech (Roche), AbbVie and Pfizer.
Does Endurx Pharmaceuticals have an API?
No public API is recorded for Endurx Pharmaceuticals.
What industry is Endurx Pharmaceuticals in?
Endurx Pharmaceuticals's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics, with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 325414 and its SIC code is 2834.